HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq:HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
Related news for (HSCS)
- HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
- Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
- HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
- HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
- HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 – Featuring CEO Andrew Simpson
